G2 Bio Companies, which includes G2 Bio Management Company and affiliates, were founded by the University of Pennsylvania Gene Therapy Program and its director Dr. James Wilson, PhD, as well as Dr. Tachi Yamada and global investment firm Temasek. Yamada has founded numerous startup companies such as Phathom Pharmaceuticals and Passage Bio and has also served as chief medical and scientific officer at Takeda Pharmaceuticals and chairperson of research and development at GlaxoSmithKline.

Temasek has committed to invest $200 million in the G2 Bio Companies, which consist of the G2 Bio Management Company and affiliates.

Tmunity expands T-cell engineered therapies partnership with Penn
Tmunity Therapeutics said it has expanded its T-cell engineered therapy collaboration with the University of Pennsylvania (Penn).

Gyroscope partners with UPenn for gene therapies targeting eye disease
Gyroscope Therapeutics has entered into a sponsored research agreement with the University of Pennsylvania (UPenn) and the Penn Center for Advanced Retinal...

Inovio to develop COVID-19 DNA-encoded monoclonal antibodies
Inovio, along with a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, has received a...

Improving the safety of gene therapies 2 different ways
Two groups of researchers have developed unique approaches to overcome the limitations of delivery of gene editing therapeutics. In a pair of new papers,...

Novel nanoparticles deliver genetic therapy to bone marrow
Specialized nanoparticles can be used to deliver small interfering RNA to the bone marrow where they can turn off specific genes in bone-marrow endothelial...